Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Lobb

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
LY303870, a centrally active neurokinin-1 antagonist with a long duration of actionS Iyengar, P A Hipskind, D R Gehlert, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivativesMary M Mader, Chuan Shih, Eileen Considine, et al.
Journal of Medicinal Chemistry|February 2, 1996
3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonistsP A Hipskind, J J Howbert, R F Bruns, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
LY303870, a centrally active neurokinin-1 antagonist with a long duration of actionS Iyengar, P A Hipskind, D R Gehlert, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivativesMary M Mader, Chuan Shih, Eileen Considine, et al.
Journal of Medicinal Chemistry|February 2, 1996
3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonistsP A Hipskind, J J Howbert, R F Bruns, et al.
Journal of Medicinal Chemistry|October 16, 2004
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agentsKaren L Lobb, Philip A Hipskind, James A Aikins, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 2